Association between specific cytogenetic subgroups and prior exposure to various chemotherapy drugs or radiation in patients with t-MDS/t-AML
Therapeutic agent . | No. patients (%)* . | Abnormality 5 (%)† . | Abnormality 7 (%)† . | Abnormalities 5 and 7 (%)† . | Balanced rearrangement (%)†‡ . | Other abnormalities (%)† . | Normal (%)† . | P . |
|---|---|---|---|---|---|---|---|---|
| Alkylator | .19 | |||||||
| Yes | 240 (82) | 44 (18) | 73 (30) | 52 (22) | 24 (10) | 30 (13) | 17 (7) | |
| No | 53 (18) | 15 (28) | 10 (19) | 9 (17) | 7 (13) | 5 (9) | 7 (13) | |
| Topoisomerase 2 inhibitor | .013 | |||||||
| Yes | 115 (39) | 16 (14) | 29 (25) | 27 (23) | 18 (16) | 19 (17) | 6 (5) | |
| No | 177 (61) | 43 (24) | 54 (31) | 34 (19) | 13 (7) | 16 (9) | 17 (10) | |
| Antimetabolite | .34 | |||||||
| Yes | 93 (32) | 15 (16) | 31 (33) | 18 (19) | 8 (9) | 10 (11) | 11 (12) | |
| No | 198 (68) | 44 (22) | 52 (26) | 43 (22) | 22 (11) | 25 (13) | 12 (6) | |
| Antitubulin | .19 | |||||||
| Yes | 158 (54) | 30 (19) | 46 (29) | 36 (23) | 13 (8) | 24 (15) | 9 (6) | |
| No | 134 (46) | 30 (22) | 37 (28) | 25 (19) | 17 (13) | 11 (8) | 14 (11) | |
| RT | .79 | |||||||
| Yes | 182 (60) | 40 (22) | 46 (25) | 40 (22) | 20 (11) | 23 (13) | 13 (7) | |
| No | 121 (40) | 21 (17) | 38 (31) | 25 (21) | 11 (9) | 15 (12) | 11 (9) |
Therapeutic agent . | No. patients (%)* . | Abnormality 5 (%)† . | Abnormality 7 (%)† . | Abnormalities 5 and 7 (%)† . | Balanced rearrangement (%)†‡ . | Other abnormalities (%)† . | Normal (%)† . | P . |
|---|---|---|---|---|---|---|---|---|
| Alkylator | .19 | |||||||
| Yes | 240 (82) | 44 (18) | 73 (30) | 52 (22) | 24 (10) | 30 (13) | 17 (7) | |
| No | 53 (18) | 15 (28) | 10 (19) | 9 (17) | 7 (13) | 5 (9) | 7 (13) | |
| Topoisomerase 2 inhibitor | .013 | |||||||
| Yes | 115 (39) | 16 (14) | 29 (25) | 27 (23) | 18 (16) | 19 (17) | 6 (5) | |
| No | 177 (61) | 43 (24) | 54 (31) | 34 (19) | 13 (7) | 16 (9) | 17 (10) | |
| Antimetabolite | .34 | |||||||
| Yes | 93 (32) | 15 (16) | 31 (33) | 18 (19) | 8 (9) | 10 (11) | 11 (12) | |
| No | 198 (68) | 44 (22) | 52 (26) | 43 (22) | 22 (11) | 25 (13) | 12 (6) | |
| Antitubulin | .19 | |||||||
| Yes | 158 (54) | 30 (19) | 46 (29) | 36 (23) | 13 (8) | 24 (15) | 9 (6) | |
| No | 134 (46) | 30 (22) | 37 (28) | 25 (19) | 17 (13) | 11 (8) | 14 (11) | |
| RT | .79 | |||||||
| Yes | 182 (60) | 40 (22) | 46 (25) | 40 (22) | 20 (11) | 23 (13) | 13 (7) | |
| No | 121 (40) | 21 (17) | 38 (31) | 25 (21) | 11 (9) | 15 (12) | 11 (9) |
Numbers in parentheses in this column are percentages within each chemotherapy agent category.
Numbers in parentheses for all other columns are percentages reported for each row of data according to cytogenetic subgroup.
Two patients, one each with abnormal chromosome 5 or 7, are counted only in the balanced rearrangement category because of t(3;21) or inv(16).